ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial

By 2024 ESMO Annual Meeting Insights Hub FEATURING Bradley McGregor

63 views

October 1, 2024

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

2024 ESMO Annual Meeting Insights Hub: GU Videos

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

236 views

3 weeks ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

View All

APCCC 2026

Fri, Feb 27, 2026

RENALC-BLADDR-PROSCA 2024

BLADDR 2024 - Hybrid Global Forum on GU Oncology

Wed, Nov 27, 2024

See 1 other

RENALC-BLADDR-PROSCA 2024

PROSCA 2024 - Hybrid Global Forum on GU Oncology

Thu, Nov 28, 2024

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

2.6K views

9 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

432 views

1 month ago

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

283 views

3 months ago

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

1.3K views

11 months ago

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

661 views

5 months ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

643 views

5 months ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

New

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

178 views

2 weeks ago

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views

1 year ago

New

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee

194 views

1 week ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

533 views

4 months ago

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

236 views

3 weeks ago

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

344 views

5 months ago

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

2024 ESMO Annual Meeting Insights Hub: GU Videos

ESMO 2024 Summary: Developmental Therapeutics Highlights

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Recommended

APCCC 2026

BLADDR 2024 - Hybrid Global Forum on GU Oncology

PROSCA 2024 - Hybrid Global Forum on GU Oncology

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Updates in the Treatment and Management of Bladder Cancer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Testosterone Suppression and Recovery in Patients With Advanced Pros…

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

Visible vs. Invisible Cancers - The Genomics and Natural History

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Developmental Therapeutics Highlights From ASCO® 2024

ESMO 2024 Summary: Developmental Therapeutics Highlights

Urothelial Carcinoma: New Developments